Ruprecht-Karls-Universitaet Heidelberg

Deutsches Krebsforschungszentrum

Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts

Joerg Schlehofer

Jean Rommelaere

Karsten Geletneky

Barbara Leuchs

Christel Herold-Mende

Olaf Witt

Irina Kiprijanova

Jeannine Lacroix

Elisabeth Hedwig Deubzer

Sonja Kern

Zahari Raykov

Marc Aprahamian

Assia Angelova

Manuel Fischer

Tanja Heimberger

Described is the use of a parvovirus, preferably H-1PV, for the therapeutical elimination of cancer stem cells (CSCs), preferably neuroblastoma stem cells and glioblastoma stem cells.

Use of parvovirus for eliminating cancer stem cells (CSCs)

Described is a pharmaceutical composition comprising (a) a parvovirus and (b) a cytokine, preferably IFN-&#x3b3;, and the use of said composition for treatment of cancer, e.g., a brain tumor.

Method for brain cancer therapy by co-administration of a parvovirus and interferon-gamma

Described is a pharmaceutical composition containing (a) a parvovirus and (b) a chemotherapeutic agent, preferably as separate entities. The parvovirus might be based on parvovirus H1, LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus (RPV), Rat virus (RV), vectors based on the foregoing viral species, and/or cells capable of actively producing the foregoing viral species. The pharmaceutical composition is beneficial for the treatment of a tumor. Tumors for which a parvovirus or the adjunction of the invention has particular utility include glioma, medulloblastoma, meningioma and pancreatic cancer. Preferred chemotherapeutic agents are gemcitabine and Temozolodine.

Parvovirus cancer therapy and combination with chemotherapy

Growing community of inventors

Leimen, Germany

Joerg Schlehofer